Clinical Trial

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2018-10-15; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2019-08-19
Trial Details
NCT Number NCT03708900
Lead Sponsor RECORDATI GROUP
Conditions Cushing Syndrome
Enrollment 12 participants
Start Date 2021-04-28
Primary Completion 2027-07-21 (estimated)
Study Completion 2027-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-03-27